Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer

• Päätekijät: Edoardo Mortato (Tekijä), Anna Paola De Caro (Tekijä), Luca Schinzari (Tekijä), Sonia Maniglio (Tekijä), Carmelo Laface (Tekijä), Gerardo Cazzato (Tekijä), Caterina Foti (Tekijä), Francesca Ambrogio (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: PAGEPress Publications, 2024-11-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Cyclin-dependent kinase (CDK) 4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, are widely used in combination with endocrine therapy for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Despite their efficacy,...